

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 Jul 2026

Evaluation the efficacy of autologous platelet rich plasma (PRP) in prevention of hypertrophic scar at the site of sternotomy in adults with open heart surgery in Shahid Modarres Hospital in 2020-2021

Protocol summary

Study aim

Determining the efficacy of autologous platelet rich plasma in prevention of hypertrophic scar at the site of sternotomy in adults with open heart surgery

Design

Participants in this study are the adults over 18 years old who undergo open heart surgery in Shahid Modarres Hospital. Each patient on who the intervention is performed will be considered as his control. This study is single-blinded so that the evaluator of the hypertrophic scar's site doesn't know the location of the PRP injection. Based on similar articles, the sample size was calculated 50 people. For sampling, the people who have the inclusion criteria enroll in the study, after signing the informed consent.

Settings and conduct

The study is conducted in Shahid Modarres hospital. The people who undergo open heart surgery and have the inclusion criteria will enroll in the study. Their wound at the site of midsternotomy is divided into two parts. Then, 4 cc of PRP is injected randomly in one part and 4 cc of normal saline as placebo in the other part. The wound site will be evaluated at 2nd, 12th and 24th weeks after surgery by a trained personnel who don't know in which part PRP has been injected.

Participants/Inclusion and exclusion criteria

Not having diabetes, autoimmune disease and thrombocytopenia; Not receiving glucocorticoids

Intervention groups

Before the surgery and injection of anesthetics and anticoagulants, a certain volume of blood is taken from the patient. PRP is prepared by an educated person with the help of a standard kit. The midsternal wound is divided into two parts. Randomly, PRP is injected into one half and normal saline solution in the other half as a placebo. Thus every patient is considered as control too. The scar formed at the wound site will be assessed at

2nd, 12th and 24th weeks after the surgery by an educated person not aware of the site of the PRP injection.

Main outcome variables

Hypertrophic scar score

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20201007048955N1**

Registration date: **2020-10-11, 1399/07/20**

Registration timing: **prospective**

Last update: **2020-10-11, 1399/07/20**

Update count: **0**

Registration date

2020-10-11, 1399/07/20

Registrant information

Name

zahra ansari aval

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2208 3095

Email address

z.ansari@sbmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-11-21, 1399/09/01

Expected recruitment end date

2021-11-22, 1400/09/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation the efficacy of autologous platelet rich plasma (PRP) in prevention of hypertrophic scar at the site of sternotomy in adults with open heart surgery in Shahid Modarres Hospital in 2020-2021

Public title

Efficacy of autologous platelet rich plasma (PRP) in prevention of hypertrophic scar

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Not having diabetes Not having autoimmune diseases
Not having thrombocytopenia(platelets below 150000)
Not receiving glucocorticoids

Exclusion criteria:

Patient not referring to the doctor for surveillance Death of the patient during the surveillance period

AgeFrom **18 years** old**Gender**

Both

Phase

N/A

Groups that have been masked

- Outcome assessor

Sample sizeTarget sample size: **50****Randomization (investigator's opinion)**

N/A

Randomization description**Blinding (investigator's opinion)**

Single blinded

Blinding description

The patients' wound at the site of mid-sternotomy is divided into upper and lower parts, then 4 cc of PRP is randomly injected in one part and 4 cc of normal saline as placebo in the other part. Patients' wounds are then assessed at 2nd, 12th and 24th weeks after surgery by another person who does not know the injection site of PRP and placebo , and the hypertrophic scars in both areas is evaluated by using the Vancouver scar scale(VSS).

Placebo

Used

Assignment

Single

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Shahid Beheshti University of Medical Sciences

Street address

Shaheed Beheshti University of Medical Sciences and Health Services, Beside Taleghani Hospital,Tabnak St. , Evin, Shaheed Chamran Highway

City

Tehran

Province

Tehran

Postal code

1985717443

Approval date

2019-02-26, 1397/12/07

Ethics committee reference number

IR.SBMU.MSP.REC.1397.782

Health conditions studied**1****Description of health condition studied**

Keloid and hypertrophic scar

ICD-10 code**ICD-10 code description****Primary outcomes****1****Description**

Hypertrophic scar score

Timepoint

2nd, 12th and 24th weeks after surgery

Method of measurement

Vancouver scar scale(VSS)

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: Before the surgery and injection of anesthetics and anticoagulants, a certain volume of blood is taken from the patient .PRP is prepared by an educated person with the help of a standard kit. The midsternal wound is divided into two parts. Randomly, PRP is injected into one half and normal saline solution in the other half as a placebo. Thus every patient himself is considered as control too. The scar formed at the wound site will be assessed at 2nd, 12th and 24th weeks after the surgery by an educated person not aware of the site

of the PRP injection.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Modarress Educational Hospital

Full name of responsible person

Sadra Ashrafi

Street address

Shahid Modarress Educational Hospital, Saadat Abad
St. Yadegare Imam Highway

City

Tehran

Province

Tehran

Postal code

1998734383

Phone

+98 21 2207 4087

Email

modarres@sbmu.ac.ir

Web page address

<http://modarres.sbmu.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Clinical Research Development Center

Full name of responsible person

Naser Malekpour

Street address

Saadatabad intersection, Yadegar Imam Highway,
Tehran

City

Tehran

Province

Tehran

Postal code

1998734383

Phone

+98 21 2207 4087

Email

Nassermalekpour@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Clinical Research Development Center

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Sadra Ashrafi

Position

Student of Medical Sciences

Latest degree

A Level or less

Other areas of specialty/work

General Practitioner

Street address

School of medicine, Shaheed Beheshti University of
Medical Sciences and Health Services, Beside
Taleghani Hospital, Tabnak St., Evin, Shaheed
Chamran Avenue

City

Tehran

Province

Tehran

Postal code

1985717443

Phone

+98 21 23871

Fax

Email

sadra.ashrafi@sbmu.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Zahra Ansari aval

Position

Deputy Director in education, Research shahid
modarres medical center

Latest degree

Subspecialist

Other areas of specialty/work

General Surgery

Street address

Shahid Modarres Hospital, Above Kaj Square, Saadat
Abad

City

Tehran

Province

Tehran

Postal code

1998734383

Phone
+98 21 2208 3095
Fax
Email
z.ansari@sbm.ac.ir

Phone
+98 21 23871
Fax
Email
sadra.ashrafi@sbm.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Sadra Ashrafi
Position
Student of Medical Sciences
Latest degree
A Level or less
Other areas of specialty/work
General Practitioner
Street address
School of medicine, Shaheed Beheshti University of
Medical Sciences and Health Services, Beside
Taleghani Hospital, Tabnak St., Evin, Shaheed
Chamran Avenue
City
Tehran
Province
Tehran
Postal code
1985717443

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

In order to protect the patients' personal information, the participants' data cannot be revealed.

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available